News

Anticipate Mycobacterial Lung Disease in Anti-TNF Users


 

EXPERT ANALYSIS FROM A SYMPOSIUM SPONSORED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY

Dr. Winthrop said he is reluctant to recommend resuming biologic therapy after a RA patient has been treated for nontuberculous mycobacterial lung disease or coccidioidomycosis.

Dr. Winthrop reported having received consultant fees from Abbott, Amgen, and Pfizer as well as research funding from Pfizer.

Pages

Recommended Reading

Infliximab Switch Clears Psoriasis in Etanercept Nonresponders
MDedge Dermatology
The Whys and How of Stopping Biologics
MDedge Dermatology
Blog: Top 10 Stories of 2011
MDedge Dermatology
Preterm Delivery a Risk in Systemic Sclerosis
MDedge Dermatology
Ondansetron Quells Methotrexate-Induced Nausea
MDedge Dermatology
Malignancy Rates Remain Stable in Ustekinumab-Treated Patients
MDedge Dermatology
Earlier Is Better in Psoriasis Treatment
MDedge Dermatology
FDA Issues Guidelines on Developing Biosimilar Products
MDedge Dermatology
Clobetasol Propionate Spray 0.05% for the Treatment of Moderate to Severe Plaque Psoriasis
MDedge Dermatology
Lasers and Light Devices for Psoriasis, Part 2: PDL, Nd:YAG Laser, CO2 Laser, and PDT
MDedge Dermatology